Physician profile
Candace Arnold
NPI 1881961365
$7,240.60
in general payments reported to CMS, 2019-2025
40 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.51 · 2022: $1,499 · 2023: $1,949 · 2024: $1,877 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,695 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,695.24 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,022.57 | 2022-2025 | Entyvio, Eohilia |
| Abbvie INC. | $859.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $787.34 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $520.88 | 2022-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $485.82 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $410.41 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $368.38 | 2022-2025 | Dupixent |
| Genzyme Corporation | $360.00 | 2022-2025 | |
| Lilly USA, LLC | $287.22 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $277.82 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $207.05 | 2024-2025 | Zenpep, Vowst |
| Evoke Pharma, INC. | $131.38 | 2022-2025 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $124.73 | 2024-2025 | Iqirvo |
| Celgene Corporation | $120.16 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $116.24 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.